These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 35973139)

  • 1. Effect of Obesity on Risk of Hospitalization, Surgery, and Serious Infection in Biologic-Treated Patients With Inflammatory Bowel Diseases: A CA-IBD Cohort Study.
    Gu P; Luo J; Kim J; Paul P; Limketkai B; Sauk JS; Park S; Parekh N; Zheng K; Rudrapatna V; Syal G; Ha C; McGovern DP; Melmed GY; Fleshner P; Eisenstein S; Ramamoorthy S; Dulai PS; Boland BS; Grunvald E; Mahadevan U; Ohno-Machado L; Sandborn WJ; Singh S
    Am J Gastroenterol; 2022 Oct; 117(10):1639-1647. PubMed ID: 35973139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative Safety and Effectiveness of Biologic Therapy for Crohn's Disease: A CA-IBD Cohort Study.
    Singh S; Kim J; Luo J; Paul P; Rudrapatna V; Park S; Zheng K; Syal G; Ha C; Fleshner P; McGovern D; Sauk JS; Limketkai B; Dulai PS; Boland BS; Eisenstein S; Ramamoorthy S; Melmed G; Mahadevan U; Sandborn WJ; Ohno-Machado L
    Clin Gastroenterol Hepatol; 2023 Aug; 21(9):2359-2369.e5. PubMed ID: 36343846
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Obesity Is Not Associated With an Increased Risk of Serious Infections in Biologic-Treated Patients With Inflammatory Bowel Diseases.
    Singh S; Heien HC; Sangaralingham L; Shah ND; Sandborn WJ
    Clin Transl Gastroenterol; 2021 Jul; 12(7):e00380. PubMed ID: 34228004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness and Safety of Biologic Therapy in Hispanic Vs Non-Hispanic Patients With Inflammatory Bowel Diseases: A CA-IBD Cohort Study.
    Nguyen NH; Luo J; Paul P; Kim J; Syal G; Ha C; Rudrapatna V; Park S; Parekh N; Zheng K; Sauk JS; Limketkai B; Fleshner P; Eisenstein S; Ramamoorthy S; Melmed G; Dulai PS; Boland BS; Mahadevan U; Sandborn WJ; Ohno-Machado L; McGovern D; Singh S
    Clin Gastroenterol Hepatol; 2023 Jan; 21(1):173-181.e5. PubMed ID: 35644340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Upfront Combination Therapy, Compared With Monotherapy, for Patients Not Previously Treated With a Biologic Agent Associates With Reduced Risk of Inflammatory Bowel Disease-related Complications in a Population-based Cohort Study.
    Targownik LE; Benchimol EI; Bernstein CN; Singh H; Lix L; Tennakoon A; Leung S; Aviña A; Coward S; Jones J; Kaplan G; Murthy SK; Nguyen GC; Peña-Sánchez JN
    Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1788-1798.e2. PubMed ID: 30448599
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Second-Line Biologic Therapy Following Tumor Necrosis Factor Antagonist Failure: A Real-World Propensity Score-Weighted Analysis.
    Ibing S; Cho JH; Böttinger EP; Ungaro RC
    Clin Gastroenterol Hepatol; 2023 Sep; 21(10):2629-2638. PubMed ID: 36787837
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Visceral adiposity and inflammatory bowel disease.
    Rowan CR; McManus J; Boland K; O'Toole A
    Int J Colorectal Dis; 2021 Nov; 36(11):2305-2319. PubMed ID: 34104989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative Outcomes and Safety of Vedolizumab vs Tumor Necrosis Factor Antagonists for Older Adults With Inflammatory Bowel Diseases.
    Singh S; Iversen AT; Allin KH; Jess T
    JAMA Netw Open; 2022 Sep; 5(9):e2234200. PubMed ID: 36178685
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High body mass index is associated with increased risk of treatment failure and surgery in biologic-treated patients with ulcerative colitis.
    Kurnool S; Nguyen NH; Proudfoot J; Dulai PS; Boland BS; Vande Casteele N; Evans E; Grunvald EL; Zarrinpar A; Sandborn WJ; Singh S
    Aliment Pharmacol Ther; 2018 Jun; 47(11):1472-1479. PubMed ID: 29665045
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative Risk of Serious Infections With Biologic Agents and Oral Small Molecules in Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis.
    Solitano V; Facciorusso A; Jess T; Ma C; Hassan C; Repici A; Jairath V; Armuzzi A; Singh S
    Clin Gastroenterol Hepatol; 2023 Apr; 21(4):907-921.e2. PubMed ID: 35944832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Frailty and Risk of Serious Infections in Biologic-treated Patients With Inflammatory Bowel Diseases.
    Singh S; Heien HC; Sangaralingham L; Shah ND; Lai JC; Sandborn WJ; Moore AA
    Inflamm Bowel Dis; 2021 Oct; 27(10):1626-1633. PubMed ID: 33325507
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative Risk of Serious Infections With Tumor Necrosis Factor α Antagonists vs Vedolizumab in Patients With Inflammatory Bowel Diseases.
    Singh S; Heien HC; Herrin J; Dulai PS; Sangaralingham L; Shah ND; Sandborn WJ
    Clin Gastroenterol Hepatol; 2022 Feb; 20(2):e74-e88. PubMed ID: 33640480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biological treatment approach to inflammatory bowel disease is similar in academic and nonacademic centres - prime time for decentralisation of inflammatory bowel disease care?
    Tepeš K; Hanžel J; Štubljar D; Strmšek K; Erjavec L; Supovec E; Jagodic Z; Končan M; Grosek J; Košir JA; Tomažič A; Kogovšek U; Norčič G; Šibli R; Žnidaršič M; Pačnik Vižintin T; Sodin B; Breznik J; Hribar VA; Ocepek A; Pernat Drobež C; Bukovnik N; Zafošnik A; Marušič T; Jurečič Brglez N; Denkovski M; Smrekar N; Novak G; Koželj M; Kurent T; Simonič J; Pintar Š; Štabuc B; Drobne D
    Eur J Gastroenterol Hepatol; 2024 Jun; 36(6):728-734. PubMed ID: 38625825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prior Immunogenicity to Anti-TNF Biologics Is Not Associated with Increased Anti-drug Antibodies to Vedolizumab or Ustekinumab.
    Costable NJ; Borman ZA; Ji J; Dubinsky MC; Ungaro RC
    Dig Dis Sci; 2022 Jun; 67(6):2480-2484. PubMed ID: 34021427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual Biologic or Small Molecule Therapy in Refractory Pediatric Inflammatory Bowel Disease (DOUBLE-PIBD): A Multicenter Study from the Pediatric IBD Porto Group of ESPGHAN.
    Yerushalmy-Feler A; Olbjorn C; Kolho KL; Aloi M; Musto F; Martin-de-Carpi J; Lozano-Ruf A; Yogev D; Matar M; Scarallo L; Bramuzzo M; de Ridder L; Kang B; Norden C; Wilson DC; Tzivinikos C; Turner D; Cohen S
    Inflamm Bowel Dis; 2024 Feb; 30(2):159-166. PubMed ID: 37042978
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined Biologic and Immunomodulatory Therapy is Superior to Monotherapy for Decreasing the Risk of Inflammatory Bowel Disease-Related Complications.
    Targownik LE; Benchimol EI; Bernstein CN; Singh H; Tennakoon A; Zubieta AA; Coward S; Jones J; Kaplan GG; Kuenzig ME; Murthy SK; Nguyen GC; Peña-Sánchez JN
    J Crohns Colitis; 2020 Oct; 14(10):1354-1363. PubMed ID: 32648579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-World Persistence of Ustekinumab in the Treatment of Inflammatory Bowel Disease.
    Bressler B; Jones J; In TSH; Lan T; Iconaru C; Marshall JK
    Adv Ther; 2023 Oct; 40(10):4421-4439. PubMed ID: 37507652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world biologic treatment and associated cost in patients with inflammatory bowel disease.
    Brandes A; Groth A; Gottschalk F; Wilke T; Ratsch BA; Orzechowski HD; Fuchs A; Deiters B; Bokemeyer B
    Z Gastroenterol; 2019 Jul; 57(7):843-851. PubMed ID: 31288280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of Serious Infections With Vedolizumab Versus Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Disease.
    Kirchgesner J; Desai RJ; Beaugerie L; Schneeweiss S; Kim SC
    Clin Gastroenterol Hepatol; 2022 Feb; 20(2):314-324.e16. PubMed ID: 33387667
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased body mass index is associated with earlier time to loss of response to infliximab in patients with inflammatory bowel disease.
    Harper JW; Sinanan MN; Zisman TL
    Inflamm Bowel Dis; 2013 Sep; 19(10):2118-24. PubMed ID: 23863401
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.